HemoCue AB Revenue and Competitors
Estimated Revenue & Valuation
- HemoCue AB's estimated annual revenue is currently $109.9M per year.
- HemoCue AB's estimated revenue per employee is $251,000
Employee Data
- HemoCue AB has 438 Employees.
- HemoCue AB grew their employee count by -4% last year.
HemoCue AB's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Engineer | Reveal Email/Phone |
2 | Chief Engineer R&D | Reveal Email/Phone |
3 | Controller | Reveal Email/Phone |
4 | Director Alliance Development | Reveal Email/Phone |
5 | Director VAVE & Manufacturing Engineering | Reveal Email/Phone |
6 | Senior Director Operations | Reveal Email/Phone |
7 | Director Channel & Sales Process Excellence | Reveal Email/Phone |
8 | IT Manager | Reveal Email/Phone |
9 | Product Support | Reveal Email/Phone |
10 | HR Business Partner | Reveal Email/Phone |
HemoCue AB Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is HemoCue AB?
HemoCue - part of the Radiometer Group, develops, produces and markets medical diagnostic products for Point of Care testing. The fundamental concept behind the HemoCue products is to perform important common blood and urine tests that offer lab quality results at the Point of Care without sacrificing the accuracy and precision offered by a central clinical lab. Tests that are fast and easy to perform - by anyone.\n\nOur Terms of Use/Guidelines\n\nWe welcome and encourage your comments and look forward to engaging with you. While you're here, we request that you follow a few basic guidelines:\n\nThis is the official HemoCue Linkedin page which may contain information on products not released in all markets. For reference on products and services available in specific markets, please go to your local HemoCue website, found on hemocue.com\n\nWe do not endorse or approve user generated content, promote any other use of our products and will remove any comments or references to such off-label use.\n\nCustomer Support\n\nIf you wish to report product complaints, side effects or adverse events events to us or have Customer Support related questions or inquiries, please contact your HemoCue representative in your country or send us an e-mail on info@hemocue.se\n\nComments\n\nTo ensure that our page provides meaningful interactions, please keep comments on topic whenever possible.\nKeep in mind that, while we want to hear your thoughts and do not intend to censor anyone, postings that are considered abusive, defamatory or obscene or that infringe copyright or other intellectual property rights of others will be removed at our discretion.\n\nWe reserve the right to remove a topic or comment at our discretion.\n\nPrivacy\n\nThe collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject as applicable, to LinkedIn's User Agreement and Privacy Policy and to HemoCue AB Data Privacy Policy, which can be found here: https://www.hemocue.com/en/about-us/legal/hemocue-online-privacy-policy
keywords:N/AN/A
Total Funding
438
Number of Employees
$109.9M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
HemoCue AB News
Diazyme Laboratories Inc. (US) Dexcom, Inc. (US) EKF Diagnostics Holdings Plc (UK) HemoCue(r) AB (Sweden) Infopia Co., Ltd. (South Korea)
... (HemoCue 201+, HemoCue AB?Hb Photometer, Angelholm, Sweden) [12]. HemoCue 201+ has reported a sensitivity of 93% and specificity of 73%...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $158.8M | 438 | -8% | N/A |
#2 | $112.2M | 438 | 10% | N/A |
#3 | $157.5M | 439 | N/A | N/A |
#4 | $120.7M | 439 | 6% | N/A |
#5 | $148.5M | 440 | 19% | N/A |